Biofrontera Q1 FY26 net loss widens to $4.75 million; revenue rises 17.4% to $10.08 million

Biofrontera Inc.

Biofrontera Inc.

BFRI

0.00
  • Biofrontera posted a net loss of USD 4.75 million for quarter ended March 31, 2026, widening from year-ago period.
  • Product revenues, net rose 17.4% to USD 10.08 million, driven by higher Ameluz net sales on 15.9% unit-volume growth; Q4 2025 price increase added about USD 0.2 million.
  • Operating loss narrowed to USD 4.32 million as cost of revenues, related party fell 40.5% to USD 1.83 million, reflecting shift from a 25% transfer-pricing model to direct cost plus a 12% earnout structure.
  • Selling, general and administrative expense climbed 27.1% to USD 10.99 million on higher selling and marketing activity, higher legal costs tied to patent-related claims, and USD 0.6 million of manufacturing-related costs.
  • ITC matter drove a USD 0.39 million patent remediation expense, with cash spending expected over 12 months following a 60-day Presidential review period ending July 6, 2026; cash and cash equivalents were USD 6.3 million at March 31, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biofrontera Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023119), on May 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.